CASI Pharmaceuticals, Inc. (CASI:NASDAQ) closed at $0.208 on February 25, 2026, unchanged on the day. It is trading at its 52-week low of $0.208. CASI Pharmaceuticals, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 22, 2025, CASI closed higher on 35 days (14%). Its best day was January 8, 2026 (+23.26%) and its worst was February 25, 2026 (-71.72%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 161 times.
CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The company's late-stage clinical drug candidates include , such as MARQIBO, a microtubule inhibitor for the treatment of adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular b-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active...
Find more stocks like CASI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.